Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nm23-H1 has been identified as a metastatic suppressor gene in murine melanoma cell lines. Several functions have been attributed to its activity in cancer, including a
histidine kinase
activity, DNA repair, and regulation of other proteins involved in metastatic formation. While in breast cancer, NM23-H1 overexpression indicates a benign status through impairing progression of disease, its function is opposite in other cancers; e.g.,
neuroblastoma
. To further understand this dichotomy of function in cancer, we have analyzed its function in prostate cancer, in which the relationship between NM23-H1 expression and prognostic state is today controversial. In vitro, overexpression of NM23-H1 in PC3 cells inhibited their cell motility, while downregulation of NM23-H1 expression in these cells by RNA interference showed enhanced cell motility. Immunohistochemistry analysis performed on 346 prostate cancer tissue samples showed a relationship between high levels of NM23-H1 expression in the nuclei of these tumorigenic cells and elevated Gleason score, with high levels of NM23-H1 cytoplasmic staining related to metastatic stage. This retrospective survival study demonstrates that high levels of NM23-H1 expression in the cytoplasm determine recurrence of prostate-specific antigen levels only in those patients with metastatic disease. Our findings suggest a correlation between high levels of NM23-H1 protein in the cytoplasm of the cells and progression of prostate cancer to metastasis, thus definitively identifying NM23-H1 as a new negative prognostic marker in prostate cancer.
...
PMID:Correlation of NM23-H1 cytoplasmic expression with metastatic stage in human prostate cancer tissue. 2155 4
Neuroblastoma
is the most common extracranial solid tumor in childhood. Gain of chromosome 17q material is found in >60% of
neuroblastoma
tumors and is associated with poor patient prognosis. The
NME1
gene is located in the 17q21.3 region, and high
NME1
expression is correlated with poor
neuroblastoma
patient outcomes. However, the functional roles and signaling activity of NME1 in
neuroblastoma
cells and tumors are unknown. NME1 and NME2 have been shown to possess histidine (His) kinase activity. Using anti-1- and 3-pHis specific monoclonal antibodies and polyclonal anti-pH118 NME1/2 antibodies, we demonstrated the presence of pH118-NME1/2 and multiple additional pHis-containing proteins in all tested
neuroblastoma
cell lines and in xenograft
neuroblastoma
tumors, supporting the presence of
histidine kinase
activity in
neuroblastoma
cells and demonstrating the potential significance of
histidine kinase
signaling in
neuroblastoma
pathogenesis. We have also demonstrated associations between NME1 expression and
neuroblastoma
cell migration and differentiation. Our demonstration of NME1 histidine phosphorylation in
neuroblastoma
and of the potential role of NME1 in
neuroblastoma
cell migration and differentiation suggest a functional role for NME1 in
neuroblastoma
pathogenesis and open the possibility of identifying new therapeutic targets and developing novel approaches to
neuroblastoma
therapy.
...
PMID:The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis. 3239 89